TrialJournal of diabetes investigation2026
Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D-PATH study).
Yuki Nakatani et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.